ApreciseKUre: an approach of Precision Medicine in a Rare Disease

被引:21
作者
Spiga, Ottavia [1 ]
Cicaloni, Vittoria [1 ,2 ]
Bernini, Andrea [1 ]
Zatkova, Andrea [3 ]
Santucci, Annalisa [1 ]
机构
[1] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy
[2] Toscana Life Sci Fdn, Siena, Italy
[3] Slovak Acad Sci, Inst Clin & Translat Res, Biomed Res Ctr, Bratislava, Slovakia
来源
BMC MEDICAL INFORMATICS AND DECISION MAKING | 2017年 / 17卷
关键词
Alkaptonuria; Rare disease; Precision Medicine; Database; Data analysis; Biomarkers; CYSTATIN-C; ALKAPTONURIA;
D O I
10.1186/s12911-017-0438-0
中图分类号
R-058 [];
学科分类号
摘要
Background: Alkaptonuria (AKU; OMIM: 203500) is a classic Mendelian genetic disorder described by Garrod already in 1902. It causes urine to turn black upon exposure to air and also leads to ochronosis as well as early osteoarthritis. Main body of the abstract: Our objective is the implementation of a Precision Medicine (PM) approach to AKU. We present here a novel ApreciseKUre database facilitating the collection, integration and analysis of patient data in order to create an AKU-dedicated "PM Ecosystem" in which genetic, biochemical and clinical resources can be shared among registered researchers. In order to exploit the ApreciseKUre database, we developed an analytic method based on Pearson's correlation coefficient and P value that generates as refreshable correlation matrix. A complete statistical analysis is obtained by associating every pair of parameters to examine the dependence between multiple variables at the same time. Short conclusions: Employing this analytic approach, we showed that some clinically used biomarkers are not suitable as prognostic biomarkers in AKU for a more reliable patients' clinical monitoring. We believe this database could be a good starting point for the creation of a new clinical management tool in AKU, which will lead to the development of a deeper knowledge network on the disease and will advance its treatment. Moreover, our approach can serve as a personalization model paradigm for other inborn errors of metabolism or rare diseases in general.
引用
收藏
页数:5
相关论文
共 16 条
  • [1] [Anonymous], 2015, PRECISION MED INITIA
  • [2] Building the foundation for genomics in precision medicine
    Aronson, Samuel J.
    Rehm, Heidi L.
    [J]. NATURE, 2015, 526 (7573) : 336 - 342
  • [3] Adult cystatin C reference intervals determined by nephelometric immunoassay
    Croda-Todd, Maria Teresa
    Soto-Montano, Xavier J.
    Hernandez-Cancino, Pedro A.
    Juarez-Aguilar, Enrique
    [J]. CLINICAL BIOCHEMISTRY, 2007, 40 (13-14) : 1084 - 1087
  • [4] Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria
    Curtis, S. L.
    Roberts, N. B.
    Ranganath, L. R.
    [J]. CLINICAL BIOCHEMISTRY, 2014, 47 (7-8) : 640 - 647
  • [5] European Commission DG Research, 2010, BIOM PAT STRAT
  • [6] Faria Bernardo, 2012, Clin Kidney J, V5, P352, DOI 10.1093/ckj/sfs079
  • [7] Garrod AE, 1902, LANCET, V2, P1616
  • [8] The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging
    Hegedus, ZL
    [J]. TOXICOLOGY, 2000, 145 (2-3) : 85 - 101
  • [9] Khalkhali-Ellis Z., 2014, Biol. Med, V6, DOI [10.4172/0974-8369.1000206, DOI 10.4172/0974-8369.1000206]
  • [10] INACTIVATION OF HUMAN CYSTATIN-C AND KININOGEN BY HUMAN CATHEPSIN-D
    LENARCIC, B
    KRASOVEC, M
    RITONJA, A
    OLAFSSON, I
    TURK, V
    [J]. FEBS LETTERS, 1991, 280 (02) : 211 - 215